You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR MITOXANTRONE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for mitoxantrone hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002003 ↗ Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas Completed Lederle Laboratories Phase 2 1969-12-31 To determine the efficacy and toxicity of the combination of mitoxantrone hydrochloride ( Novantrone ) and etoposide in the treatment of patients with HIV associated lymphomas.
NCT00002259 ↗ Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma Completed Lederle Laboratories Phase 2 1969-12-31 To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.
NCT00002474 ↗ Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer Completed Loyola University Phase 2 1991-02-01 RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow transplant may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy and autologous bone marrow transplant work in treating patients with refractory or recurrent ovarian cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for mitoxantrone hydrochloride

Condition Name

Condition Name for mitoxantrone hydrochloride
Intervention Trials
Leukemia 49
Acute Myeloid Leukemia 45
Prostate Cancer 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for mitoxantrone hydrochloride
Intervention Trials
Leukemia 181
Leukemia, Myeloid, Acute 134
Leukemia, Myeloid 133
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for mitoxantrone hydrochloride

Trials by Country

Trials by Country for mitoxantrone hydrochloride
Location Trials
Canada 140
China 86
Germany 64
Australia 56
Spain 56
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for mitoxantrone hydrochloride
Location Trials
California 62
New York 55
Ohio 49
Illinois 49
Texas 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for mitoxantrone hydrochloride

Clinical Trial Phase

Clinical Trial Phase for mitoxantrone hydrochloride
Clinical Trial Phase Trials
Phase 4 13
Phase 3 82
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for mitoxantrone hydrochloride
Clinical Trial Phase Trials
Completed 181
Recruiting 47
Terminated 46
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for mitoxantrone hydrochloride

Sponsor Name

Sponsor Name for mitoxantrone hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 74
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 27
Fred Hutchinson Cancer Research Center 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for mitoxantrone hydrochloride
Sponsor Trials
Other 414
Industry 182
NIH 75
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.